Biomarkers in First Episode Schizophrenia

Completed

Conditions studied: Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Depressed Type

In brief

This study will identify and evaluate relevant biomarkers and structural brain imaging for understanding potential biological illness related mechanisms in medication-naïve subjects with early psychosis before and after initiation of antipsychotic medication

Key facts

Study ID

NCT02033382

Run by

NYU Langone Health

People needed

165

Starts

2012-07-01

Expected to finish

2014-12-01

Last updated by the study team

2021-01-14

Who can join

Age: 16 and older, up to 40. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Male or female
• Ages 15-40 years
• Schizophrenia, any subtype or Schizophreniform disorder
• Sufficient proficiency in English or Spanish to complete assessments (US)

You may not qualify if…

• Major depression by the Diagnostic and Statistical Manual of Mental Disorders IV criteria
• Calgary Depression Scale for Schizophrenia (CDSS) score of 7 or greater.
• Clinical Global Assessment of Severity of Suicidality of 3 (moderate) or greater.
• Serious suicide attempt within three years
• Treatment with an antipsychotic or antidepressant within the last six months
• Active alcohol or other substance abuse or dependence within one month
• Unstable medical illness

Where it is running

• Bellevue Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.